In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are…
Read More
In this article by Allie Nawrat, our co-founder and CEO Ben Zeskind discusses Immuneering’s recent financing of $62m, in an oversubscribed Series B round led by high-profile life science investors….
In this article by Michael Fitzhugh, Immuneering co-founder and CEO Ben Zeskind discusses the company’s recent oversubscribed Series B financing, which raised a total of $62M to advance its Disease…
Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.
In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…
